Analyst Ratings For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Today, Berenberg Bank initiated coverage on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) with a Buy.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Buy with a consensus target price of $64.1250 per share, a potential 50.28% upside.
Some recent analyst ratings include
- 12/13/2018-Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has coverage initiated with a Buy rating
- 11/23/2018-Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had its Overweight rating reiterated by Cantor Fitzgerald
- 3/21/2018-Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had its Positive ➝ Buy rating reiterated by Citigroup with a $62.00 price target
- On 8/15/2018 Steven W Spector, EVP, sold 29,005 with an average share price of $36.01 per share and the total transaction amounting to $1,044,470.05.
- On 4/16/2018 Steven W Spector, EVP, sold 30,001 with an average share price of $34.57 per share and the total transaction amounting to $1,037,134.57.
- On 5/12/2017 Amit Munshi, Insider, bought 25,000 with an average share price of $1.19 per share and the total transaction amounting to $29,750.00.
- On 4/26/2017 Amit Munshi, Insider, bought 50,000 with an average share price of $1.41 per share and the total transaction amounting to $70,500.00.
- On 6/13/2016 Christine Anna White, Director, sold 18,728 with an average share price of $1.99 per share and the total transaction amounting to $37,268.72.
- On 3/30/2015 Randall E Woods, Director, sold 76,268 with an average share price of $4.49 per share and the total transaction amounting to $342,443.32.
- On 3/17/2015 Steven W Spector, EVP, sold 70,000 with an average share price of $5.00 per share and the total transaction amounting to $350,000.00.
About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Recent Trading Activity for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals, Inc. closed the previous trading session at 42,67 up +1,70 4,15 % with 41.5 shares trading hands.